Home Hero
Home Hero

With AMVUTTRA® (vutrisiran) for the treatment of the polyneuropathy
of hATTR amyloidosis in adults, your patients may1

FEEL MORE IN THE MOMENT1-3

AMVUTTRA may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing 4 times per year1,3

AMVUTTRA may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing 4 times per year1,3

AMVUTTRA may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing 4 times per year1,3

At 9 months in a randomized, open-label study, patients treated with AMVUTTRA once every 3 months were compared with an external placebo group and demonstrated:

Improvement in neuropathy impairment, as measured by mNIS+71,3

Improvement in quality of life, as measured by Norfolk QoL-DN1,3

Improvement in gait speed, as measured by 10MWT1,3

10MWT=10-meter walk test; hATTR=hereditary transthyretin-mediated; mNIS+7=modified Neuropathy Impairment Score + 7; Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy.

Explore the pivotal study design and the efficacy and safety of AMVUTTRA

Clinical profile

Learn how to administer AMVUTTRA

Dosing and administration

Find out how to get your patients started with AMVUTTRA

Start form
Treatment center icon
Find a treatment center
Locate the treatment center closest to your patient.
View the directory
Circle check icon
Stay informed
Receive relevant content and updates.
Sign up

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Vinik EJ, Vinik AI. In: Farquhar I, Summers KH, Sorkin A, eds. The Value of Innovation: Impact on Health, Life Quality, Safety, and Regulatory Research. Bingley, UK: Emerald Group Publishing Ltd; 2007;16:29-52.
  3. Adams D, Tournev IL, Taylor MS, et al. Amyloid. 2022. Published online July 23, 2022. doi.org/10.1080/13506129.2022.2091985.